reports
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results an...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, N...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on ...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the thi...
Tenet Healthcare Corp: 1 director
A director at Tenet Healthcare Corp sold 4,000 shares at 155.936USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
- Gary Brode
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October ...
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologis...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
SPX Testing Resistance as Rate Cut Cycle Begins The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 57...
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
THC TENET HEALTHCARE CORPORATION
SGRY SURGERY PARTNERS INC.
SEM SELECT MEDICAL HOLDINGS CORPORATION
PFG PRINCIPAL FINANCIAL GROUP INC.
NDAQ NASDAQ INC.
MKTX MARKETAXESS HOLDINGS INC.
MFC. MANULIFE FINANCIAL CORPORATION
IBKR INTERACTIVE BROKERS GROUP INC. CLASS A
HCA HCA HEALTHCARE INC
CME CME GROUP INC. CLASS A
CBOE CBOE GLOBAL MARKETS INC
PRU PRUDENTIAL FINANCIAL INC.
VIRT VIRTU FINANCIAL INC. CLASS A
MET METLIFE INC.
CYH COMMUNITY HEALTH SYSTEMS INC.
ICE CANLAN ICE SPORTS
SLF SALAFIN
SNEX STONEX GROUP INC
EQH EQUITABLE HOLDINGS INC.
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Upgrading Consumer Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow Our long-term outlook remains neutral on the S&P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023. In late-July (7/30/24 Compass) we discussed expectations for a 1- to 4-month pullback/consolidation period on the SPX and Nasdaq 100 (QQQ), and at this point it seems likely to last closer to four months, and potentially 4- to 6-months from our selected 7/17/2...
VGR VECTOR GROUP LTD.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
THC TENET HEALTHCARE CORPORATION
PSA PUBLIC STORAGE
MO ALTRIA GROUP INC
HCA HCA HEALTHCARE INC
CUBE CUBESMART
CYH COMMUNITY HEALTH SYSTEMS INC.
NSA NATIONAL STORAGE AFFILIATES TRUST
BMTA BRITISH AMERICAN TOBACCO PLC ADS
TPB TURNING POINT BRANDS
PM PHILIP MORRIS INTERNATIONAL INC.
IMBBY IMPERIAL BRANDS PLC
- Gary Brode
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global...
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also ...
- Jonathan Moreland
- Jonathan Moreland
NCR NCR CORPORATION
TTSH TILE SHOP HOLDINGS INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PCRX PACIRA BIOSCIENCES INC.
ORRF ORRSTOWN FINANCIAL SERVICES INC.
OEC ORION ENGINEERED CARBONS SA
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
CRK COMSTOCK RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
CLOV CLOVER PAKISTAN LTD.
YUMC YUM CHINA HOLDINGS INC.
GBDC GOLUB CAPITAL BDC INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
SCPH SCPHARMACEUTICALS INC
EYE NATIONAL VISION HOLDINGS
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
MGTX MEIRAGTX HOLDINGS PLC
HMNF HMN FINANCIAL INC.
ELAN ELANCO ANIMAL HEALTH INC.
LYFT LYFT
GRX INC.
NVST THE GABELLI HEALTHCARE & WELLNESSRX TRUST
XAIR ENVISTA HOLDINGS
GRWG BEYOND AIR
PGEN GROWGENERATION
ALTG PRECIGEN INC
ONEW ALTA EQUIPMENT GROUP INC.
TLS ONEWATER MARINE
FTCI TELOS
RPHM FTC SOLAR
VMEO INC.
TMCI RENEO PHARMACEUTICALS
TSE INC.
QSI VIMEO INC
PFHC TREACE MED CONCEPTS INC
RXO_w TRINSEO PLC
WRBY QUANTUM-SI INC
GRNT PROFRAC HLDG CORP
MBC_w RXO INC
FCCND WARBY PARKER INC
ET GRANITE RIDGE RESOURCES INC
GT MASTERBRAND INC
MIO SPECTRAL CAPITAL CORP
FIP ENERGY TRANSFER LP
GOODYEAR TIRE & RUBBER CO.
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
FTAI INFRASTRUCTURE INC
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PAYC PAYCOM SOFTWARE INC.
CRK COMSTOCK RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
INTT INTEST CORP.
YUMC YUM CHINA HOLDINGS INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SCPH SCPHARMACEUTICALS INC
HHS HARTE-HANKS INC.
FF FIRST MINING GOLD
FGBI FIRST GUARANTY BANCSHARES
XAIR BEYOND AIR
GRWG GROWGENERATION
BIGC BIGCOMMERCE HOLDINGS
CVRX INC.
TMCI CVRX
FLNC INC.
PFHC TREACE MED CONCEPTS INC
LAW FLUENCE ENERGY INC
PROFRAC HLDG CORP
CS DISCO INC
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results a...
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scP...
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up ...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $12...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commerciali...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.